Predictors of Relapses or Recurrences in Patients With Giant Cell Arteritis: A Medical Records Review Study.
Journal
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
ISSN: 1536-7355
Titre abrégé: J Clin Rheumatol
Pays: United States
ID NLM: 9518034
Informations de publication
Date de publication:
01 Jun 2023
01 Jun 2023
Historique:
medline:
22
5
2023
pubmed:
3
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
Giant cell arteritis (GCA) is the most common systemic vasculitis in individuals aged ≥50 years. Its course is marked by a high relapse rate requiring long-term glucocorticoid use with its inherent adverse effects. We aimed to identify factors associated with relapses or recurrences in GCA at diagnosis. We reviewed the medical records of consecutive patients with GCA diagnosed between 2009 and 2019 and followed for at least 12 months. We recorded their characteristics at onset and during follow-up. Factors associated with relapses or recurrences were identified using multivariable analysis. We included 153 patients, among whom 68% were female with a median age of 73 (47-98) years and a median follow-up of 32 (12-142) months. Seventy-four patients (48.4%) had at least 1 relapse or recurrence. Headache and polymyalgia rheumatica were the most frequent manifestations of relapses. The first relapse occurred at a median time of 13 months after the diagnosis, with a median dose of 5.5 (0-25) mg/d of glucocorticoids.In multivariable analysis, patients with relapses or recurrences had a higher frequency of cough and scalp tenderness at diagnosis (20.3% vs 5.1%; odds ratio [OR], 4.73; 95% confidence interval [CI], 1.25-17.94; p = 0.022; and 41.9% vs 29.1%; OR, 2.4; 95% CI, 1.07-5.39; p = 0.034, respectively). Patients with diabetes mellitus at diagnosis had fewer relapses or recurrences during follow-up (5.4% vs 19%; OR, 0.24; 95% CI, 0.07-0.83; p = 0.024). Cough and scalp tenderness at diagnosis were associated with relapses or recurrences, whereas patients with diabetes experienced fewer relapses or recurrences.
Identifiants
pubmed: 36727749
doi: 10.1097/RHU.0000000000001942
pii: 00124743-202306000-00012
doi:
Substances chimiques
Glucocorticoids
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25-e31Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet . 2008;372:234–245.
Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum . 2013;65:1–11.
Salvarani C, Pipitone N, Versari A, et al. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol . 2012;8:509–521.
Ciofalo A, Gulotta G, Iannella G, et al. Giant cell arteritis (GCA): pathogenesis, clinical aspects and treatment approaches. Curr Rheumatol Rev . 2019;15:259–268.
Prieto-González S, Arguis P, García-Martínez A, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis . 2012;71:1170–1176.
Kermani TA, Warrington KJ, Crowson CS, et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis . 2013;72:1989–1994.
Muratore F, Kermani TA, Crowson CS, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford) . 2015;54:463–470.
Daumas A, Rossi P, Bernard-Guervilly F, et al. Clinical, laboratory, radiological features, and outcome in 26 patients with aortic involvement amongst a case series of 63 patients with giant cell arteritis [in French]. Rev Med Interne . 2014;35:4–15.
de Boysson H, Liozon E, Lambert M, et al. 18 F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis: a multicenter cohort of 130 patients. Medicine (Baltimore) . 2016;95:e3851.
Bienvenu B, Ly KH, Lambert M, et al. Management of giant cell arteritis: recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne . 2016;37:154–165.
Kermani TA, Warrington KJ, Cuthbertson D, et al. Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol . 2015;42:1213–1217.
Martinez-Lado L, Calviño-Díaz C, Piñeiro A, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine . 2011;90:186–193.
Alba MA, García-Martínez A, Prieto-González S, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore) . 2014;93:194–201.
Restuccia G, Boiardi L, Cavazza A, et al. Flares in biopsy-proven giant cell arteritis in Northern Italy: characteristics and predictors in a long-term follow-up study. Medicine (Baltimore) . 2016;95:e3524.
Labarca C, Koster MJ, Crowson CS, et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford) . 2016;55:347–356.
Leon L, Rodriguez-Rodriguez L, Morado I, et al. Treatment with methotrexate and risk of relapses in patients with giant cell arteritis in clinical practice. Clin Exp Rheumatol . 2018;36(Suppl 111):121–128.
Gérard A-L, Simon-Tillaux N, Yordanov Y, et al. Efficacy and safety of steroid-sparing treatments in giant cell arteritis according to the glucocorticoids tapering regimen: a systematic review and meta-analysis. Eur J Intern Med . 2021;88:96–103.
Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum . 2003;49:703–708.
Dumont A, Parienti J-J, Delmas C, et al. Factors associated with relapse and dependence on glucocorticoids in giant cell arteritis. J Rheumatol . 2020;47:108–116.
Makhzoum J-P, Grayson PC, Ponte C, et al. Pulmonary involvement in primary systemic vasculitides. Rheumatology (Oxford) . 2021;61:319–330.
Hori H, Kobashigawa T, Fukuchi T, et al. Giant cell arteritis manifested by chronic dry cough. BMJ Case Rep . 2020;13:e234734.
Zenone T, Puget M. Dry cough is a frequent manifestation of giant cell arteritis. Rheumatol Int . 2013;33:2165–2168.
Imran TF, Helfgott S. Respiratory and otolaryngologic manifestations of giant cell arteritis. Clin Exp Rheumatol . 2015;33:S-164–S-170.
Becourt-Verlomme C, Barouky R, Alexandre C, et al. Inaugural symptoms of Horton's disease in a series of 260 patients [in French]. Rev Med Interne . 2001;22:631–637.
Manganelli P, Fietta P, Carotti M, et al. Respiratory system involvement in systemic vasculitides. Clin Exp Rheumatol . 2006;24:S48–S59.
Hernández-Rodríguez J, García-Martínez A, Casademont J, et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum . 2002;47:29–35.
Ungprasert P, Upala S, Sanguankeo A, et al. Patients with giant cell arteritis have a lower prevalence of diabetes mellitus: a systematic review and meta-analysis. Mod Rheumatol . 2016;26:410–414.
Wadström K, Jacobsson L, Mohammad AJ, et al. Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis. Rheumatology (Oxford) . 2020;59:3229–3236.
Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era? J Diabetes Complications . 2020;34:107723.
Wiciński M, Górski K, Wódkiewicz E, et al. Vasculoprotective effects of vildagliptin. Focus on atherogenesis. Int J Mol Sci . 2020;21:E2275.
Espitia O, Néel A, Leux C, et al. Giant cell arteritis with or without aortitis at diagnosis. A retrospective study of 22 patients with longterm followup. J Rheumatol . 2012;39:2157–2162.
Hellmich B, Agueda A, Monti S, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis . 2020;79:19–30.